A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone Across All Treatment Lines in Patients with MSI-high or dMMR mCRC By Ogkologos - February 5, 2025 628 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Efficacy of Afamitresgene Autoleucel for HLA-A*02-positive and MAGE-A4-positive Synovial Sarcoma Following... April 2, 2024 Singer Surprises 6-Year-Old Fan Who Beat Cancer With Trip To Disney January 10, 2022 Geriatric Assessment Intervention Reduces Patient-Reported Symptomatic Toxicities in Older Patients with... November 17, 2022 Cancer “Decoys” Planted Underneath The Skin Lure In Cancer Cells And... November 4, 2019 Load more HOT NEWS FDA Grants Accelerated Approval to Adagrasib with Cetuximab for KRAS G12C-mutated... Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than... What to Know About Mastectomy With Flat Closure After a Breast... FDA Approves Selinexor for Refractory or Relapsed Multiple Myeloma
